Fuyuan Pharmaceutical announced that the company recently received a drug registration certificate for risedronate tablets issued by the State Drug Administration and approved the production of the drug. This drug is used to treat and prevent osteoporosis in postmenopausal women. It is classified as a chemical class 3, and the drug approval number is Chinese medicine approval number H20265470. Obtaining a drug registration certificate this time is considered to have passed the consistency evaluation. As of the announcement date, the company's total R&D investment for this drug was RMB 8.026 million.

Fuyuan Pharmaceutical announced that the company recently received a drug registration certificate for risedronate tablets issued by the State Drug Administration and approved the production of the drug. This drug is used to treat and prevent osteoporosis in postmenopausal women. It is classified as a chemical class 3, and the drug approval number is Chinese medicine approval number H20265470. Obtaining a drug registration certificate this time is considered to have passed the consistency evaluation. As of the announcement date, the company's total R&D investment for this drug was RMB 8.026 million.